ElenaGabrielaChioreanMD

Gastrointestinal Cancer

Professor, Medicine, U of WA Sch of Med

Overview of Dr. Chiorean

Dr. Elena Chiorean is an oncologist in Seattle, WA and is affiliated with multiple hospitals in the area, including Seattle Cancer Care Alliance, University of Washington Medical Center, and University of Washington Medical Center. She received her medical degree from Iuliu Hatieganu University of Medicine and Pharmacy and has been in practice 24 years. Dr. Chiorean accepts several types of health insurance, listed below. She is one of 136 doctors at University of Washington Medical Center and one of 144 doctors at Seattle Cancer Care Alliance who specialize in Oncology.

Office
825 Eastlake Ave East
G4830
Seattle, WA 98108
Book by Phone855-287-1360
Fax(206) 606-2140
Is this information wrong?

Education & Training

University of MinnesotaFELLOWSHIP
William Beaumont HospitalRESIDENCY
Iuliu Hatieganu University of Medicine and PharmacyMEDICAL_SCHOOL

Certifications & Licensure

WA State Medical License 2012 - 2019
WA State Medical License 2012 - 2021
IN State Medical License 2004 - 2013
MN State Medical License 1999 - 2004
MI State Medical License 1997 - 2001
American Board of Internal Medicine Medical Oncology

Clinical Trials

Afatinib Dimaleate and Capecitabine in Treating Patients With Advanced Refractory Solid Tumors, Pancreatic Cancer or Biliary Cancer Start of enrollment: 2015 Nov 01Chiorean E.,Chiorean E.G.,Shahda S.
Phase II Study of SPI-1620 in Combination With Docetaxel as a Second-Line to Treat Biliary Cancer Start of enrollment: 2013 Apr 01Schinkel, A.,Lima, C.R.,Inman, C.,Portnoy, D.,Chiorean, E.,Gandhi, J.,Mertz-Rivera, K.,White, L.,Amin, M.,Haley, M.,Choi, M.R.,Kim, R.
Safety and Efficacy Study of PRI-724 Plus Gemcitabine in Subjects With Advanced or Metastatic Pancreatic Adenocarcinoma Start of enrollment: 2013 Apr 01Ko, A.,Cress, A.E.,Northfelt, D.W.,Northfelt, D.W.,Chiorean, E.G.,Kwak, E.L.,Kindler, H.,Lenz, H.,McWilliams, R.R.,McWilliams, R.R.
Phase II Study of Pegylated Liposomal Doxorubicin (Doxil®) and Temsirolimus (Torisel®) in Patients With Advanced Hepatocellular Cancer Start of enrollment: 2011 Jun 01Chiorean, E.G.,Goff, L.W.,Lockhart, A.C.,Morse, M.
A Randomized Phase II Study of Irinotecan and Cetuximab With or Without the Anti-Angiogenic Antibody, Ramucirumab (IMC-1121B), in Advanced, K-ras Wild-Type Colorectal Cancer Following Progression on Bevacizumab-Containing Chemotherapy Start of enrollment: 2010 Nov 01Agarwala, S.S.,Alden, M.,Asik, A.,Bayer, G.K.,Behrens, R.J.,Benson, A.B.,Chiorean, E.G.,Cohen, D.J.,Constantinou, C.L.,Dakhil, S.R.,Flynn, P.J.,Fuloria, J.,Gilman, P.B.,Hamad, A.,Hochster, H.S.,Jones, T.I...
Randomized Phase II Study of Everolimus Alone Versus Everolimus Plus Bevacizumab in Patients With Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors Start of enrollment: 2010 Oct 01Arriaga, Y.E.,Atkins, J.N.,Behrens, R.J.,Benson, A.B.,Berenberg, J.L.,Chiorean, E.G.,Conlin, A.K.,Constantinou, C.L.,Dakhil, S.R.,Finn, N.G.,Flynn, P.J.,Fuloria, J.,Giguere, J.K.,Gross, H.M.,Grubbs, S.S.,...
A Phase III Trial of 6 Versus 12 Treatments of Adjuvant FOLFOX Plus Celecoxib or Placebo for Patients With Resected Stage III Colon Cancer Start of enrollment: 2010 Jun 01(Gbenga), O.O.,Advani, A.S.,Agarwala, S.S.,Ahmed, S.,Al-Hazzouri, A.,Ansari, R.H.,Ardman, B.,Asik, A.,Atkins, J.N.,Averbook, B.J.,Aziz, S.,Bar-Lev, A.,Barhamand, F.B.,Bathini, V.G.,Behrens, R.J.,Benson, A...
Cancer Care Engineering of Colorectal Cancer - OMICs Pilot Study Start of enrollment: 2009 Jan 01Chiorean, E.,Chiorean, E.G.,Flynn, J.
Sorafenib and Bevacizumab in Combination With Paclitaxel in Patients With Solid Tumors Start of enrollment: 2008 Jul 01Matei, D.E.,Chiorean, E.G.
Erlotinib in Combination With Docetaxel in Advanced Hepatocellular and Biliary Tract Carcinomas Start of enrollment: 2007 Sep 01Chiorean, E.G.
Metabolomics-Based Detection of Colorectal Cancer Start of enrollment: 2007 Jul 01Chiorean, E.
Capecitabine + Irinotecan Followed by Combined Modality Capecitabine and Radiation in Locally Advanced Rectal Cancer Start of enrollment: 2005 Jan 01Chiorean, E.G.
Join now to see all

Publications & Presentations

PubMed

Surgical Outcome Results From SWOG S1505: A Randomized Clinical Trial of mFOLFIRINOX Versus Gemcitabine/Nab-paclitaxel for Perioperative Treatment of Resectable Pancre...
Ahmad, S. A., Duong, M., Sohal, D. P., Gandhi, N. S., Beg, M. S., Wang-Gillam, A., Wade, J. L., Chiorean, E. G., Guthrie, K. A., Lowy, A. M., Philip, P. A., Hochster, ...> ;Annals of surgery. 2020 Aug 3
Real-world comparative effectiveness of nab-paclitaxel plus gemcitabine <i>versus</i> FOLFIRINOX in advanced pancreatic cancer: a systematic review.
Chiorean, E. G., Cheung, W. Y., Giordano, G., Kim, G., Al-Batran, S.> ;Therapeutic advances in medical oncology. 2019 Jun 18
Biomarker-driven and molecularly targeted therapies for pancreatic adenocarcinoma.
Zhen, D. B., Coveler, A., Zanon, S., Reni, M., Chiorean, E. G.> ;Seminars in oncology. 2018 Nov 6
The role of GLI-SOX2 signaling axis for gemcitabine resistance in pancreatic cancer.
Jia, Y.,Gu, D.,Wan, J.,Yu, B.,Zhang, X.,Chiorean, E. G.,Wang, Y.,Xie, J.> ;Oncogene. 2018 Nov 02
The role of the folate pathway in pancreatic cancer risk.
Chittiboyina, S.,Chen, Z.,Chiorean, E. G.,Kamendulis, L. M.,Hocevar, B. A.> ;PLoS ONE. 2018 Feb 24
Phase 2 study of treatment selection based on tumor thymidylate synthase expression in previously untreated patients with metastatic colorectal cancer: A trial of the ...
Meropol, N. J., Feng, Y., Grem, J. L., Mulcahy, M. F., Catalano, P. J., Kauh, J. S., Hall, M. J., Saltzman, J. N., George, T. J., Zangmeister, J., Chiorean, E. G., Che...> ;Cancer. 2017 Dec 7
Phase I/II study of mocetinostat in combination with gemcitabine for patients with advanced pancreatic cancer and other advanced solid tumors.
Chan, E.,Chiorean, E. G.,O'Dwyer, P. J.,Gabrail, N. Y.,Alcindor, T.,Potvin, D.,Chao, R.,Hurwitz, H.> ;Cancer Chemother. Pharmacol.. 2017 Dec 15
Altered metabolite levels and correlations in patients with colorectal cancer and polyps detected using seemingly unrelated regression analysis.
Chen, C.,Gowda, GAN.,Zhu, J.,Deng, L.,Gu, H.,Chiorean, E. G.,Zaid, M. A.,Harrison, M.,Zhang, D.,Zhang, M.,Raftery, D.> ;Metabolomics. 2017 Nov 01
Second-line therapy after nab-paclitaxel plus gemcitabine or after gemcitabine for patients with metastatic pancreatic cancer.
Chiorean EG, Von Hoff DD, Tabernero J, El-Maraghi R, Wee Ma W, Reni M, Harris M, Whorf R, Liu H, Shiansong Li J, Manax V, Romano A, Lu B, Goldstein D> ;Br. J. Cancer. 2016-10-25
Phase 1 study of the anti-vascular endothelial growth factor receptor 3 monoclonal antibody LY3022856/IMC-3C5 in patients with advanced and refractory solid tumors and...
Saif MW, Knost JA, Chiorean EG, Kambhampati SRP, Yu D, Pytowski B, Qin A, Kauh JS, O'Neil BH> ;Cancer Chemother. Pharmacol.. 2016-10-01
Combining NMR and LC/MS Using Backward Variable Elimination: Metabolomics Analysis of Colorectal Cancer, Polyps, and Healthy Controls.
Deng L, Gu H, Zhu J, Nagana Gowda GA, Djukovic D, Chiorean EG, Raftery D> ;Anal. Chem.. 2016-08-16
Positron emission tomography (PET) as a predictive measure in patients with metastatic pancreatic cancer and normal CA19-9 levels at baseline.
Ramanathan RK, Korn RL, Chiorean EG, Liu H, Von Hoff DD> ;Ann. Oncol.. 2016-08-01
Second-line therapy after nab-paclitaxel plus gemcitabine or after gemcitabine for patients with metastatic pancreatic cancer.
Chiorean EG, Von Hoff DD, Tabernero J, El-Maraghi R, Ma WW, Reni M, Harris M, Whorf R, Liu H, Li JS, Manax V, Romano A, Lu B, Goldstein D> ;Br. J. Cancer. 2016-07-12
Localized Pancreatic Cancer: Multidisciplinary Management.
Coveler, A. L.,Herman, J. M.,Simeone, D. M.,Chiorean, E. G.> ;Am Soc Clin Oncol Educ Book. 2016 May 01
Algenpantucel-L immunotherapy in pancreatic adenocarcinoma.
Coveler, A. L.,Rossi, G. R.,Vahanian, N. N.,Link, C.,Chiorean, E. G.> ;Immunotherapy. 2016 Jan 21
9 citations
CA19-9 decrease at 8 weeks as a predictor of overall survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alon...
Chiorean, E. G., Von Hoff, D. D., Reni, M., Arena, F. P., Infante, J. R., Bathini, V. G., Wood, T. E., Mainwaring, P. N., Muldoon, R. T., Clingan, P. R., Kunzmann, V.,...> ;Annals of oncology : official journal of the European Society for Medical Oncology. 2016 Jan 24
Localized Pancreatic Cancer: Multidisciplinary Management.
Coveler AL, Herman JM, Simeone DM, Chiorean EG> ;Am Soc Clin Oncol Educ Book. 2016-01-01
Ocular metastasis of colorectal cancer: An uncommon presentation of a common malignancy.
Khawaja MR, Minturn JT, Spittler AJ, Chiorean EG> ;Hematol Oncol Stem Cell Ther. 2015-12-01
Pancreatic cancer: Update on Immunotherapies and Algenpantucel-L.
McCormick, K. A.,Coveler, A. L.,Rossi, G. R.,Vahanian, N. N.,Link, C.,Chiorean, E. G.> ;Hum Vaccin Immunother. 2015 Dec 01
10 citations
Targeted serum metabolite profiling and sequential metabolite ratio analysis for colorectal cancer progression monitoring.
Zhu, J., Djukovic, D., Deng, L., Gu, H., Himmati, F., Abu Zaid, M., Chiorean, E. G., Raftery, D.> ;Analytical and bioanalytical chemistry. 2015 Sep 8
17 citations
Pancreatic cancer: optimizing treatment options, new, and emerging targeted therapies.
Chiorean, E. G., Coveler, A. L.> ;Drug design, development and therapy. 2015 Jul 18
9 citations
Exploring Metabolic Profile Differences between Colorectal Polyp Patients and Controls Using Seemingly Unrelated Regression.
Chen, C., Deng, L., Wei, S., Gowda, G. A., Gu, H., Chiorean, E. G., Abu Zaid, M., Harrison, M. L., Pekny, J. F., Loehrer, P. J., Zhang, D., Zhang, M., Raftery, D.> ;Journal of proteome research. 2015 Apr 29
Metabolomics method to comprehensively analyze amino acids in different domains.
Gu, H.,Du, J.,Carnevale Neto, F.,Carroll, P. A.,Turner, S. J.,Chiorean, E. G.,Eisenman, R. N.,Raftery, D.> ;Analyst. 2015 Feb 24
29 citations
Phase I study of every 2- or 3-week dosing of ramucirumab, a human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2 in...
Chiorean, E. G., Hurwitz, H. I., Cohen, R. B., Schwartz, J. D., Dalal, R. P., Fox, F. E., Gao, L., Sweeney, C. J.> ;Annals of oncology : official journal of the European Society for Medical Oncology. 2015 Mar 20
15 citations
A Phase I First-in-Human Study of Enoticumab (REGN421), a Fully Human Delta-like Ligand 4 (Dll4) Monoclonal Antibody in Patients with Advanced Solid Tumors.
Chiorean, E. G., LoRusso, P., Strother, R. M., Diamond, J. R., Younger, A., Messersmith, W. A., Adriaens, L., Liu, L., Kao, R. J., DiCioccio, A. T., Kostic, A., Leek, ...> ;Clinical cancer research : an official journal of the American Association for Cancer Research. 2015 Mar 1
Join now to see all

Lectures

The Role of GLI-SOX2 Signaling Axis for Gemcitabine Resistance in Pancreatic Cancer
2019 ASCO Annual Meeting - 6/1/2019

Hospital Affiliations

Seattle Cancer Care AllianceSeattle, Washington
University of Washington Medical CenterSeattle, Washington
University of Washington Medical CenterSeattle, Washington

Insurance Accepted

Aetna Choice POS II
Aetna HMO
Anthem Blue Access PPO
Anthem Blue Preferred HMO
BCBS Blue Card PPO
BCBS Illinois PPO
BCBS North Carolina BlueOptions PPO
CIGNA HMO
CIGNA Open Access
CIGNA PPO
Cofinity PPO
First Health PPO
Great West PPO
HealthLink PPO
Humana ChoiceCare Network PPO
Multiplan PHCS PPO
Multiplan PPO
Sagamore Health Plus
United Healthcare - Direct Choice Plus POS
United Healthcare - Direct Options PPO
Please verify your coverage with the provider's office directly when scheduling an appointment

ElenaGabrielaChioreanMD

Overview of Dr. Chiorean

Education & Training

Certifications & Licensure

Clinical Trials

Publications & Presentations

Hospital Affiliations

Insurance Accepted

About

Clinicians

Partners

ElenaGabrielaChioreanMD

Overview of Dr. Chiorean

Education & Training

Certifications & Licensure

Clinical Trials

Publications & Presentations

Hospital Affiliations

Insurance Accepted

Viewing the full profile is available to verified healthcare professionals only.

About

Clinicians

Partners